Pieris has deployed its Anticalin drug discovery platform to identify first- and best-in-class multispecific drug candidates, including tumor-targeted T cell agonists and multi-checkpoint antagonists. Key components to the Company's IO franchise is a fully proprietary, targeted 4-1BB agonist; a strategic alliance with Servier with fully retained US rights on several programs; and an IO-focused R&D partnership with the world leading oncology company, Roche.
Learn More »
Pieris is developing a diversified pipeline of inhaled Anticalin® molecules to locally address respiratory disease via inhalation and has established a transformative collaboration with AstraZeneca to access industry-leading formulation and device capabilities and accelerate the time to market of these drug candidates. The five-program, worldwide alliance provides co-development and co-commercialization options for Pieris' lead respiratory program, PRS-060, as well as two additional programs.
Learn More »